Alterations of the expression and activity of midbrain nitric oxide synthase and soluble guanylyl cyclase in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinsonism in mice

Neuroscience

Volumn 141, Issue 2, 2006, Pages 1033-1046

  Chalimoniuk, M ^a   Lukacova, N ^b   Marsala, J ^b   Langfort, J ^a  

^a MOSSAKOWSKI MEDICAL RESEARCH CENTRE   (Poland)

^b INSTITUTE OF CHEMISTRY   (Slovakia)

Author keywords

1 methyl 4 phenyl 1,2,3,6 tetrahydropyridine; guanylyl cyclase; neuronal nitric oxide synthase; Parkinson's disease; substantia nigra pars compacta

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 7 NITROINDAZOLE; CYCLIC GMP; GUANYLATE CYCLASE; MESSENGER RNA; NITRIC OXIDE SYNTHASE; PHOSPHODIESTERASE; PROTEIN;

ANALYTIC METHOD; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN REGION; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; ENZYME ACTIVATION; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MALE; MESENCEPHALON; MOUSE; NERVE DEGENERATION; NONHUMAN; PARKINSONISM; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SUBSTANTIA NIGRA;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANALYSIS OF VARIANCE; ANIMALS; CELL COUNT; CYCLIC GMP; DISEASE MODELS, ANIMAL; DRUG ADMINISTRATION SCHEDULE; GENE EXPRESSION REGULATION; GUANYLATE CYCLASE; IMMUNOHISTOCHEMISTRY; INDAZOLES; MALE; MESENCEPHALON; MICE; MICE, INBRED C57BL; NEUROPROTECTIVE AGENTS; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE I; PARKINSONIAN DISORDERS; TIME FACTORS; TYROSINE 3-MONOOXYGENASE;

EID: 33745991786     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2006.04.022     Document Type: Article

References (69)

1. Barthwal M.K., Srivastava M., and Dikshit M. Role of nitric oxide in a progressive neurodegeneration model of Parkinson's disease in the rat. Redox Rep 6 (2001) 297-302
2. Beal M.F. Aging, energy and oxidative stress in neurodegenerative diseases. Ann Neurol 38 (1995) 357-366
3. Bharath S., Hsu M., Kaur D., Rajagopalan S., and Andersen J.K. Glutathione, iron and Parkinson's disease. Biochem Pharmacol 64 (2002) 1037-1048
4. Boje K.M. Nitric oxide neurotoxicity in neurodegenerative diseases. Front Biosci 9 (2004) 763-776
5. Bonkale W.L., Winblad B., Ravid R., and Cowburn R.F. Reduced nitric oxide responsive soluble guanylyl cyclase activity in superior temporal cortex of patients with Alzheimer's disease. Neurosci Lett 187 (1995) 5-8
6. Braak H., Del Tredici K., Rub U., de Vos R.A., Jansen Stur E.N., and Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 24 (2003) 197-211
7. Bredt D.S., Galatt C.E., Huang P.L., Fotuhi P.L., Dawson T.M., and Snyder S.H. Nitric oxide synthase protein and mRNA are discretely localized in neuronal populations of the mammalian CNS together with NADPH diaphorase. Neuron 7 (1991) 615-624
8. Canals S., Casarejos M.J., de Bernardo S., Rodriguez-Marti E., and Mena M.A. Glutathione depletion switches nitric oxide neurotrophic effects to cell death in midbrain cultures. implications for Parkinson's disease. J Neurochem 79 (2001) 1183-1195
9. Canals S., Casarejos M.J., de Bernardo S., Rodriguez-Marti E., and Mena M.A. Nitric oxide triggers the toxicity due to glutathione depletion in midbrain cultures through 12-lipogenase. J Biol Chem 278 (2003) 21542-21549
10. Chalimoniuk M., Langfort J., Lukacova N., and Marsala J. Upregulation of guanylyl cyclase expression and activity in striatum of MTPT-induced parkinsonism in mice. Biochem Biophys Res Commun 324 (2004) 118-126
11. Chen Z.S., Lee K., and Kruh G.D. Transport of cyclic nucleotides and estradiol 17-β-D-glucuronide by multidrug resistance protein 4. resistance to 6-mercaptopurine and 6-thioguanine. J Biol Chem 276 (2001) 33747-33754
12. de Vente J., Hopkins D.A., Markerink-van Ittersum M., and Steinbusch H.W.M. Distribution of nitric oxide synthase and nitric oxide-receptive, cGMP-producing structures in the rat brain. Neuroscience 87 (1998) 207-241
13. de Vente J., Hopkins D.A., Markerink-van Ittersum M., and Steinbusch H.W.M. Effects of the 3′,5′-phosphodiesterase inhibitors isobutylmethylxanthine and zaprinast on NO-mediated cGMP accumulation in the hippocampus slice preparation. an immunocytochemical study. J Chem Neuroanat 10 (1996) 241-248
14. de Vente J., Markerink-van Ittersum M., van Abeelen J., Emson P.C., Axer H., and Steinbusch H.W.M. NO-mediated cGMP synthesis in cholinergic neurons in the rat forebrain. effects of lesioning dopaminergic or serotoninergic pathways on nNOS and cGMP synthesis. Eur J Neurosci 12 (2000) 507-519
15. Dehmer T., Lindenau J., Haid S., Dichgans J., and Schulz J.B. Deficiency of inducible nitric oxide synthase protects against MPTP toxicity in vivo. J Neurochem 74 (2000) 2213-2216
16. Di Monte D.A., Royland J.E., Anderson A., Catagnoli K., Catagnoli Jr. N., and Langston J.W. Inhibition of monoamine oxidase contributes to the protect effect of 7-nitroindazole against MPTP neurotoxicity. J Neurochem 69 (1997) 1771-1773
17. Dunnett S.B., and Bjorklund A. Prospects for new restorative and neuroprotective treatments in Parkinson's disease. Nature 399 (1999) A32-A39
18. Fahn S., and Przedborski S. Parkinsonism. In: Rowland L.P. (Ed). Merritt's neurology (2000), Lippincott Williams & Wilkins, New York 679-693
19. Ferrante R.J., Kowall N.W., Beal M.F., Richardson E.P., Bird E.D., and Matin J.B. Selective sparing of a class of striatum neurons in Huntington's disease. Science 230 (1999) 561-563
20. Gibb B., and Garthwaite J. Subunit of nitric oxide receptor, soluble guanylyl cyclase, expressed in rat brain. Eur J Neurosci 13 (2001) 539-544
21. Gupta G., Atam M., Yang L., and Danzinger R.S. The β2 subunit inhibits stimulation of the α1/β1form of soluble guanylyl cyclase by nitric oxide. Potential relevance to regulation of blood pressure. J Clin Invest 100 (1997) 1488-1492
22. Hallman H., Lange I., Olson L., Stromberg I., and Jonsson G. Neurochemical and histological characterization of neurotoxic effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on brain catecholamine neurons in mouse. J Neurochem 44 (1985) 117-127
23. He Y., Imam S.Z., Dong Z., Jankovic J., Ali S.F., Appel S.H., and Le W. Role of nitric oxide in rotenone-induced nigro-striatal injury. J Neurochem 86 (2003) 1338-1345
24. Heikkila R.E., Hess A., and Duviosin R.C. Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice. Science 224 (1984) 1451-1453
25. Hirrlinger J., Konig J., and Dringen R. Expression of mRNAs of multidrug resistance proteins (MRPS) in cultured rat astrocytes, oligodendrocytes, microglial cells and neurons. J Neurochem 82 (2002) 716-779
26. Hornykiewicz O. Biochemical aspects of Parkinson's disease. Neurology 51 (1998) S2-S9
27. Ibarra C., Nedvetsky P.I., Gerlach M., Riederer P., and Schmidt H.H.H.W. Regional and age-dependent expression of the nitric oxide receptor, soluble guanylyl cyclase, in the human brain. Brain Res 907 (2001) 54-60
28. Iravani M.M., Kashefi K., Mander P., Rose S., and Jenner P. Involvement of inducible nitric oxide synthase in inflammation-induced dopaminergic neurodegeneration. Neuroscience 110 (2002) 49-58
29. Jedlitschky G., Burchell B., and Keppler D. The multidrug resistance protein 5 (MRP5) functions as an ATP-dependent export pump for cyclic nucleotides. J Biol Chem 275 (2000) 30069-30074
30. Jenner P. Oxidative mechanisms in nigral cell death in Parkinson's disease. Mov Disord 13 Suppl 1 (1998) 24-34
31. Johnston G.A.R., and Balcar V.J. High affinity uptake of cyclic AMP in rat brain slices. Brain Res 59 (1973) 451-453
32. Klivenyi P., Andreassen O.A., Ferrante R.J., Lancelot E., Reif D., and Beal M.F. Inhibition of neuronal nitric oxide synthase protects against MPTP toxicity. Neuroreport 11 (2000) 1265-1268
33. Klivenyi P., Beal M.F., Ferrante R.J., Andreassen O.A., Wermer M., Chin M.R., and Bonventre J.V. Mice deficient in group IV cytosolic phospholipase A2 are resistant to MPTP neurotoxicity. J Neurochem 71 (1998) 2634-2637
34. Koesling D., and Friebe A. Enzymology of soluble guanylyl cyclase. In: Mayer B. (Ed). Nitric oxide (2000), Springer, Berlin 93-109
35. Koglin M., Vehse K., Budaeus L., Scholz H., and Behrends S. Nitric oxide activates the beta 2 subunit of soluble guanylyl cyclase in the absence of a second subunit. J Biol Chem 276 (2001) 30737-30743
36. Kurosaki R., Muramatsu Y., Michmata M., Matsubara M., Kato H., Imai Y., Itoyama Y., and Araki T. Role of nitric oxide synthase against MPTP neurotoxicity in mice. Neurol Res 24 (2002) 655-662
37. Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227 (1970) 680-685
38. Li Y., Maher P., and Schubert D. Requirement for cGMP in nerve cell death caused by glutathione depletion. J Cell Biol 139 (1997) 1317-1324
39. Linden D.J., Dawson T.M., and Dawson V.L. An evaluation of the nitric oxide/cGMP/cGMP-dependent protein kinase cascade in the induction of cerebellar long-term depression in culture. J Neurosci 15 (1995) 5098-5105
40. Lowry O.H., Rosebrough N.J., Farr A.L., and Randell R.J. Protein measurement with Folin phenol reagent. J Biol Chem 193 (1951) 265-275
41. Luo D.S., Leung E., and Vincent S.R. Nitric oxide-dependent efflux of cGMP in rat cerebellar cortex. an in-vivo microdialysis study. J Neurosci 14 (1994) 261-271
42. Muramatsu Y., Kurosaki R., Mikami T., Michimata M., Matsubara M., Imai Y., Kato H., Itoyama Y., and Araki T. Therapeutic effect of neuronal nitric oxide synthase inhibitor (7-nitroindazole) against MPTP neurotoxicity in mice. Metab Brain Dis 17 (2002) 169-182
43. Muramatsu Y., Kurosaki R., Watanabe H., Michmata M., Matsubara M., Imai Y., and Araki T. Cerebral alterations in a MPTP-mouse model of Parkinson's disease. an immunocytochemical study. J Neural Transm 110 (2003) 1129-1144
44. Nies A.T., Jedlitschky G., Konig J., Herold-Mende C., Steiner H.H., Schmit H.P., and Keppler D. Expression and immunolocalization of the multidrug resistance proteins, MRP1-MRP6 (ABCC1-ABCC6), in human brain. Neuroscience 129 (2004) 349-360
45. Paxinos G., and Franklin K.B.J. The mouse brain in stereotaxic coordinates. 2nd edition (2004), Academic Press, London, UK
46. Petroske E., Meredith G.E., Callen S., Totterdell S., and Lau Y.-S. Mouse model of Parkinsonism. a comparison between subacute MPTP and chronic MPTP/probenecid treatment. Neuroscience 106 (2001) 589-601
47. Prickaerts J., Staveren W.C.G., Sik A., Markerink-van Ittersum M., Niewohner U., van der Staay F.-J., Blokland A., and de Vente J. Effects of two selective phosphodiesterase type 5 inhibitors, sedenafil and vardenafil, on object recognition memory and hippocampal cGMP levels in the rat. Neuroscience 113 (2002) 351-361
48. Przedborski S., and Jackson-Lewis V. Mechanism of MPTP toxicity. Mov Disord 13 Suppl 1 (1998) 35-38
49. Przedborski S., Jackson-Lewis V., Yokoyama R., Shibata T., Dawson V.L., and Dawson T.M. Role of neuronal nitric oxide in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity. Proc Natl Acad Sci U S A 93 (1996) 4565-4571
50. Przedborski S., Vila M., Jackson-Lewis V., and Dawson T.M. Reply. A new look at pathogenesis of Parkinson's disease. Trends Pharmacol Sci 21 (2000) 165-170
51. Ricaurte G.A., Langston J.W., Delanney L.E., Irwin I., Peroutus S.J., and Forno L.S. Fate of nigrostriatal neurons in young mature mice given 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. A neurochemical and morphological reassessment. Brain Res 376 (1986) 117-124
52. Russwurm M., Behrends S., Harteneck C., and Koesling D. Functional properties of a naturally occurring isoform of soluble guanylyl cyclase. Biochem J 335 (1998) 125-130
53. Sager G. Cyclic GMP transporters. Neurochem Int 45 (2004) 865-873
54. Sarre S., Yuan H., Jonkers N., Van Hemelrijck A., Ebinger G., and Michotte Y. In vivo characterization of somatodendritic dopamine release in the substantia nigra of 6-hydroxydopamine-lesioned rats. J Neurochem 90 (2004) 29-39
55. Sauer H., and Oertel W.H. Progressive degeneration of nigrostriatal dopamine neurons following intrastriatal terminal lesions with 6-hydroxydopamine. a combined retrograde tracing and immunocytochemical study in the rat. Neuroscience 59 (1994) 401-415
56. Schapira A.H.V. Oxidative stress in Parkinson's disease. Neuropathol Appl Neurobiol 21 (1996) 3-9
57. Sharina I.G., Krumenacker J.S., Martin E., and Murad F. Genomic organization of alpha 1 and beta 1 subunits of the mammalian soluble guanylyl cyclase genes. Proc Natl Acad Sci U S A 97 (2000) 10878-10883
58. Sian J., Dexter D.T., and Lees A.J. Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia. Ann Neurol 36 (1994) 348-355
59. Sofic E., Lange K.W., Jellinger K., and Riederer P. Reduced and oxidized glutathione in substantia nigra of patients with Parkinson's disease. Neurosci Lett 142 (1992) 128-130
60. Southam E., and Garthwaite J. The nitric oxide-cyclic GMP signaling pathway in rat brain. Neuropharmacology 32 (1993) 1267-1277
61. Strosznajder J.B., and Chalimoniuk M. Biphasic enhancement of nitric oxide synthase activity and cGMP level following brain ischemia in gerbils. Acta Neurobiol Exp 56 (1996) 71-81
62. Suenobu N., Shichiri M., Iwashina M., Marumo F., and Hirata Y. Natriuretic peptides and nitric oxide induced endothelial apoptosis via a cGMP-dependent mechanism. Arterioscler Thromb Vasc Biol 19 (1999) 140-146
63. Tariq M., Khan H.A., Al Moutaery K., and Al Deeb S. Protective effect of quinacrine on striatal dopamine levels in 6-OHDA and MPTP models of Parkinsonism in rodents. Brain Res Bull 54 (2001) 77-82
64. Touyz R.M., Picard S., Schiffrin E.L., and Deshepper C.F. Cyclic GMP inhibits a pharmacologically distinct Na+/H+ exchanger variant in cultured rat astrocytes via an extracellular site of action. J Neurochem 68 (1997) 1451-1461
65. van Muiswinkel F.L., Steinbusch H.W.M., Drukarch B., and de Vente J. Identification of NO-producing and receptive cells in mesencephalic transplants in a rat model of Parkinson's disease. a study using NADPH-d enzyme- and NOSc/cGMP immunocytochemistry. Ann N Y Acad Sci 738 (1994) 289-304
66. van Staveren W.C.G., Markerink-van Ittersum M., Steinbusch H.W.M., and de Vente J. The effects of phosphodiesterase inhibition on cyclic GMP and cyclic AMP accumulation in the hippocampus of the rat. Brain Res 888 (2001) 275-286
67. Watanabe H., Muramatsu Y., Kurosaki R., Michmata M., Matsubara M., Imai Y., and Araki T. Protective effects of neuronal nitric oxide synthase inhibitor in mouse brain against MPTP neurotoxicity. an immunohistological study. Eur Neuropharmacol 14 (2004) 93-104
68. Wijnholds J., Mol C.A.A.A.M., van Deemter L., de Haas M., Scheffer G., Baas F., Beijnen J.H., Scheper R., Hatse S., De Clereq E., Balzarini J., and Borst P. Multidrug-resistant protein 5 is a multispecific organic anion transporter able to transport nucleotide analogs. Proc Natl Acad Sci U S A 97 (2000) 1798-1804
69. Zhang Y., Dawson V.L., and Dawson T.M. Oxidative stress and genetics in the pathogenesis of Parkinson's disease. Neurobiol Dis 7 (2000) 240-250